Giannis Mountzios
@g_mountzios
Followers
3K
Following
10K
Media
806
Statuses
6K
#MedicalOncologist MSc Transl Res Univ Paris Sud #LungCancer biology, immunotherapy, clinical trials #LCSM @myESMO faculty @iaslc live to give
Athens
Joined July 2015
Being part of a history-making drug that helps pts with #SCLC live longer and better is the biggest reward a thoracic oncologist could hope for. Grateful being involved and to our pts Just out in @NEJM Presentation today by 1@only @charlesrudin
#ASCO25
23
45
213
📣 Registration for #ELCC26 is open! Join us in Copenhagen, 25–28 March, for cutting-edge science and global networking. ⏰ Early rates until 21 Jan. 🔗 https://t.co/ytlMYvMwGv Don’t miss your chance to shape the future of #LungCancer care! @IASLC @APassaroMD @DrSanjayPopat
0
7
11
Stellar talk by @LeiDeng3 @fredhutch @mecmededucation in Seattle new drugs in NSCLC explosion of new agents in trials FDA approved or in clinical trials! @DimaDanai @RahulBanerjeeMD @mshadman @VenurVyshak @CParkMD @g_mountzios @StephenVLiu @JackWestMD @n8pennell @CharuAggarwalMD
0
7
27
I had the honor and the huge pleasure to meet @anguspratt at WCLC 2024 in San Diego, where we shared the same round table discussion focusing on rare genetic and their huge impact on Lung cancer prognosis I will never forget his sharp spirit, his breaking humor , his passion
.@anguspratt was a giant in the lung cancer community. An advocate, friend, and warm, unforgettable presence. His legacy lives on in the research and advocacy he championed. We feel the weight of his loss, and we’ll continue the work that meant so much to him.
0
1
14
Excellent NEOLA Phase 2 trial, demonstrating the safety of induction with osimertinib prior to CRT in EGFRm patients with unresectable Stage III. Great ORR as expected and interesting reduction of the radiotherapy field. Awaiting EFS and OS data…#ESMOAsia25
1
21
40
#ESMOAsia2025 Lung Orals🔥 Ph II Trispecific T-cell Engager Alveltamig in pre-Tx SCLC: - 60pts - ORR 53.3% (10mg), 56.7% (30mg), near 60% still responding at 9m - TRAEs: pyrexia, CRS, vomiting, no g3+ CRS (10mg), no ICANS Promising #ESMOAmbassadors @myESMO @OncoAlert #LCSM
2
25
56
GTA182 a new PRMT5 inhibitor in MTAPdeletion tumors with intracranial activity Promosing results and good safety profike -Best test for detecting MTAP deletion: NGS, IHC? -15% NSCLC are MTAPdel, specially those with AGAs, role for combining PRMT5 inh + TKI? #ESMOASIA25
0
17
43
Excellent overview by @JordiRemon on the latest developments in uncommon EGFR mutations... very interesting efficacy of 3rd generation EGFR TKIs! #EGFR #ESMOASIA25
0
21
67
Uncommon / PACC EGFR mut NSCLC are 10% of all EGFRm.Afatinib is the unique drug approved in this subset. Enozertinib (ORIC-114):promising activity in PACC EGFRm in 3L with intracranial activity Other “competitors” : furmonertinib, zipalertinib, amivantamab+lazertinib #ESMOASIA25
0
25
66
Congratulations to everyone who matched for their fellowships 2026. For those who went unmatched; life has more mysteries to unravel, introspect today .. and RISE up again tomorrow :)
0
2
15
Don't love the update in NCCN Guidelines re: cMET IHC to guide telisotuzumab vedotin. While HGFR and cMET here are synonyms, the label and trials use the cMET terminology. Worried that this will increase confusion, particularly to those not dedicated to thoracic alone...
1
11
62
Looking forward to a great discussion and to see you!
What defined progress in 2025 for targeted therapies and ADCs? At our roundtable, @MartinReck2 will walk through the most influential data in targeted treatments and antibody drug conjugates, highlighting how these advances are reshaping decision making in NSCLC. Together with
0
1
3
@iaslc friends- you want to learn the skills to become an effective leader? Then apply to below new competitive/global program! #lcsm
New from IASLC! Apply to the Leadership Development Program for global mentorship, training, and a WCLC 2026 workshop. Apps open Dec 1; due Jan 15. Limited spots — apply early! https://t.co/IxkKPGA8LF
1
7
26
Results from amivantamab + lazertinib in atypical EGFR mutant NSCLC from CHRYSALIS-2 (cohort C) @JCO_ASCO (n=105). RR 52%, DOR 14.1m, PFS 11.1m and as first-line, RR 57%, DOR 20.7m, PFS 19.5m. Similar RR for solitary vs compound. In PACC mt, RR 45%. https://t.co/vBPTbhklFM
ascopubs.org
PURPOSEFor patients with advanced non–small cell lung cancer (NSCLC) harboring atypical epidermal growth factor receptor (EGFR) mutations (eg, S768I, L861Q, G719X), efficacy of current treatment...
0
29
81
Proud to share our SAKK 15/19 phase II trial, the first Swiss multicenter study testing thoracic radiotherapy conomitantly with IO maintenance after chemo-IO in ES-SCLC. ➡️ TRT + durvalumab was safe, improved local control (only 27% thoracic relapse), though the primary endpoint
ejcancer.com
Small cell lung cancer (SCLC) is an aggressive tumour type accounting for 10–15 % of lung cancers. The role of thoracic radiotherapy (TRT) in extensive stage SCLC (ES_SCLC) in the era of checkpoint...
4
15
46
Look out for this upcoming episode of the @IASLC podcast, Lung Cancer Considered, where we discuss antibody drug conjugates (ADCs) in EGFR NSCLC including datopotamab deruxtecan (Dato-DXd) and sacituzumab tirumotecan (Sac-TMT) with Drs. @ElaineShumMD and Li Zhang.
0
6
47
💔 There are no easy words for this. Our friend and absolute force in the lung cancer community, Ashley (Onelunglady), passed away yesterday. Her loss will be felt everywhere. She made people feel seen. She built connections instantly. This hurts. We love you, Ashley 💔
1
13
47
Today we have had our Autumn 🍁EORTC LCG meeting. A multidisciplinary group discussing new trials in the treatment landscape of thoracic malignancies. New ideas💡for trials and discussions in a friendly ambience. Thanks all for the feedback! @EORTC
0
8
26
19ΝΟV2025, a day to remember: 2️⃣ approvals by @FDA in the lung cancer space: 1. #Sevabertinib for pretreated HER2 TKD mutant #NSCLC just 2 weeks after @NEJM publication @LeXiuning 2. #tarlatamab in pretreated #SCLC regular approval (accel in 5/2024). Still No regular acces
1
2
10